ES2068191T3 - Conjugados anticuerpo-enzima en combinacion con profarmacos para el suministro de agentes citotoxicos a celulas tumorales. - Google Patents

Conjugados anticuerpo-enzima en combinacion con profarmacos para el suministro de agentes citotoxicos a celulas tumorales.

Info

Publication number
ES2068191T3
ES2068191T3 ES88112646T ES88112646T ES2068191T3 ES 2068191 T3 ES2068191 T3 ES 2068191T3 ES 88112646 T ES88112646 T ES 88112646T ES 88112646 T ES88112646 T ES 88112646T ES 2068191 T3 ES2068191 T3 ES 2068191T3
Authority
ES
Spain
Prior art keywords
enzyme
administration
antibody
tumor cells
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88112646T
Other languages
English (en)
Inventor
Peter D Senter
Mark G Saulnier
Joseph P Brown
David E Kerr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/211,301 external-priority patent/US4975278A/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2068191T3 publication Critical patent/ES2068191T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ESTE INVENCION REVELA UN NUEVO METODO PARA LA INTRODUCCION DE DROGAS CITOTOXICAS EN CELULAS TUMORALES A TRAVES DE LA ADMINISTRACION DE UN COMPLEJO ANTICUERPO - ENZIMA ESPECIFICO PARA EL TUMOR QUE SE UNE A LAS CELULAS TUMURALES, SEGUIDA DE LA ADMINISTRACION DE UN PRECURSOR DE LA DROGA QUE SUFRE UNA TRANSFORMACION EN EL MISMO EMPLAZAMIENTO DEL TUMOR, EN PRESENCIA DE LA ENZIMA LIGADA AL ANTICUERPO, DANDO COMO RESULTADO UNA DROGA CITOTOXICA ACTIVA. DE ACUERDO CON LAS ESPECIFICACIONES DE LA INVENCION, COMPLEJOS ANTICUERPO - ENZIMA CONTENIENDO LA ENZIMA FOSFATOSA ALCALINA (AP), HAN SIDO UTILIZADAS CON EL NUEVO PRECURSOR DE LA DROGA, UN ETAPOSIDO - 4 - FOSFATO O 7 - (2 - AMINOETILFOSFATO)MITOMICINA, O UNA COMBINACION DE AMBOS, CONSIGUIENDO UNA ELEVADA EFECTIVIDAD EN LA DESTRUCCION DE CELULAS CANCEROSAS. DE ACUERDO OTRA DE LAS ESPICIFICACIONES DE LA INVENCION, UN COMPLEJO ANTICUERPO - ENZIMA CONTENIENDO LA ENZIMA PENICILINA V AMIDOSA (PVA) A SIDO UTILIZADO CON UN NUEVO PRECURSOR DE DROGA, LA N - (P - HIDROXIFENOSCIACETIL) ADRIAMICINA CON ALTA EFECTIVIDAD EN LA DESTRUCCION DE CELULAS TUMORALES.
ES88112646T 1987-08-04 1988-08-03 Conjugados anticuerpo-enzima en combinacion con profarmacos para el suministro de agentes citotoxicos a celulas tumorales. Expired - Lifetime ES2068191T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8138287A 1987-08-04 1987-08-04
US16106888A 1988-02-26 1988-02-26
US07/211,301 US4975278A (en) 1988-02-26 1988-06-29 Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells

Publications (1)

Publication Number Publication Date
ES2068191T3 true ES2068191T3 (es) 1995-04-16

Family

ID=27373967

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88112646T Expired - Lifetime ES2068191T3 (es) 1987-08-04 1988-08-03 Conjugados anticuerpo-enzima en combinacion con profarmacos para el suministro de agentes citotoxicos a celulas tumorales.

Country Status (19)

Country Link
EP (2) EP0540859B1 (es)
JP (2) JP2738414B2 (es)
KR (1) KR930006757B1 (es)
AT (2) ATE162196T1 (es)
AU (1) AU614532B2 (es)
CA (1) CA1336887C (es)
DE (2) DE3853028T2 (es)
DK (1) DK175406B1 (es)
EG (1) EG18751A (es)
ES (1) ES2068191T3 (es)
FI (1) FI98197C (es)
GR (1) GR3015065T3 (es)
HU (1) HU207230B (es)
IE (2) IE950981L (es)
IL (1) IL87319A (es)
NO (1) NO178138C (es)
NZ (1) NZ225599A (es)
PT (2) PT88187B (es)
YU (1) YU150888A (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
JP3273608B2 (ja) * 1989-01-23 2002-04-08 アクゾ・エヌ・ヴエー 治療薬の部位特異的インビボ活性化
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
GB8907617D0 (en) * 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
DE3935016A1 (de) * 1989-10-20 1991-04-25 Behringwerke Ag Glycosyl-etoposid-prodrugs, verfahren zu ihrer herstellung und ihre anwendung in kombination mit funktionalisiertem tumorspezifischen enzym-konjugaten
FI94362C (fi) * 1989-10-20 1995-08-25 Squibb Bristol Myers Co Oleellisesti puhdistettu sulfataasi, menetelmä sen valmistamiseksi ja sitä tuottava Streptomyces-kanta
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US5270196A (en) * 1989-10-20 1993-12-14 Bristol-Myers Squibb Company Arylsulfatase from streptomyces
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
WO1991008770A1 (en) * 1989-12-11 1991-06-27 Immunomedics, Inc. Method for antibody targeting of diagnostic or therapeutic agents
CA2069439A1 (en) * 1989-12-15 1991-06-16 Susumu Iwasa Monoclonal antibodies, their production and use
GB9001641D0 (en) * 1990-01-24 1990-03-21 Imp Cancer Res Tech Compounds
KR920007937B1 (ko) * 1990-01-30 1992-09-19 현대자동차 주식회사 밸브시트용 철(Fe)계 소결합금
DE4002888A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Anthracyclin-glycosyl-prodrugs, verfahren zu ihrer herstellung und ihre verwendung in kombination mit funktionalisierten tumorspezifischen enzymkonjugaten
CA2078118C (en) * 1990-04-25 1999-11-16 Paul A. Aristoff Cc-1065 analogs
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
GB9200417D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
DE4233152A1 (de) 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5459248A (en) * 1993-11-04 1995-10-17 Bristol-Myers Squibb Company Process of preparing etoposide phosphate and etoposide
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
US5516679A (en) * 1994-12-23 1996-05-14 Bristol-Myers Squibb Company Penicillin V amidohydrolase gene from Fusarium oxysporum
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
JPH1160499A (ja) * 1997-08-22 1999-03-02 Hiroshi Maeda 抗腫瘍剤
US6159706A (en) * 1997-12-23 2000-12-12 Newbiotics, Inc. Application of enzyme prodrugs as anti-infective agents
ATE499115T1 (de) * 1998-09-18 2011-03-15 Immunomedics Inc Antikörper verwiesene enzymprodrugtherapie mit glukuronidase
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US7514067B2 (en) * 2000-04-25 2009-04-07 President And Fellows Of Harvard College Methods for tumor diagnosis and therapy
WO2001093826A1 (fr) * 2000-06-06 2001-12-13 Sumitomo Pharmaceuticals Company, Limited Preparations polymere synthetiques biocompatibles
US7445802B2 (en) 2000-12-26 2008-11-04 Yeda Research And Development Co. Ltd Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
AU2002358086B2 (en) * 2001-12-03 2009-06-04 Universitatsklinikum Charite Der Humboldt-Universitat Zu Berlin Technologie Transferstelle Podophyllotoxins as antiproliferative agents
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
EP1735350B1 (en) * 2004-04-15 2010-08-25 Genencor International, Inc. Anti-cea scfv - beta-lactamase constructs (cab molecules) in adept
EP2061493A4 (en) * 2006-08-21 2011-01-12 Essential Skincare Llc COMPOSITIONS FOR REDUCING OR PREVENTING SKIN CANCER
BR112020013244A2 (pt) * 2018-01-04 2020-12-01 Shanghai Lumosa Therapeutics Co., Ltd. proteínas de fusão de anticorpo citosina-desaminase de domínio único

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1578734A (es) * 1967-11-28 1969-08-22
FR2122695A5 (en) * 1971-01-20 1972-09-01 Rhone Poulenc Sa Antibiotics duborimycin and 27706rp - by reduction of daunorubicin and adriamycin
FR2397425A1 (fr) 1977-07-11 1979-02-09 Rhone Poulenc Ind Nouveaux derives de la daunorubicine, leur preparation et les compositions qui les contiennent
CA1168150A (en) * 1981-12-18 1984-05-29 The Governors Of The University Of Alberta Targeting conjugates of albumin and therapeutic agents
FR2523445A1 (fr) 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
EP0142905A2 (en) 1983-03-30 1985-05-29 Bio-Response Inc. Therapeutic substance for treating diseases such as cancer
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
WO1986003201A1 (en) * 1984-11-23 1986-06-05 Sri International C-glycosidic adriamycin analogs
US4906562A (en) 1984-12-21 1990-03-06 Oncogen Monocolonal antibodies and antigen for human non-small cell lung carcinomas
DE3500023A1 (de) * 1985-01-02 1986-07-10 Farmitalia Carlo Erba S.p.A., Mailand/Milano 4'-desoxyanthracyclinester
FR2584294B1 (fr) * 1985-07-08 1992-02-21 Berdal Pascal Compositions pharmaceutiques a visee cytotrophique
GB8528761D0 (en) * 1985-11-22 1985-12-24 Axon Healthcare Ltd Enzyme-coupled antibodies
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems

Also Published As

Publication number Publication date
PT101702A (pt) 1996-01-31
FI98197C (fi) 1997-05-12
YU150888A (en) 1990-06-30
NO178138C (no) 1996-01-31
DK175406B1 (da) 2004-09-27
IE950981L (en) 1989-02-04
JP3127136B2 (ja) 2001-01-22
JPH02223532A (ja) 1990-09-05
KR930006757B1 (ko) 1993-07-23
IL87319A (en) 1995-08-31
EP0540859A1 (en) 1993-05-12
DE3853028T2 (de) 1995-12-14
IE882379L (en) 1989-02-04
IL87319A0 (en) 1990-02-09
DK434188A (da) 1989-02-05
GR3015065T3 (en) 1995-05-31
KR890003408A (ko) 1989-04-14
EP0302473A2 (en) 1989-02-08
DE3856112D1 (de) 1998-02-19
NO178138B (no) 1995-10-23
ATE162196T1 (de) 1998-01-15
AU614532B2 (en) 1991-09-05
AU2020188A (en) 1989-05-25
FI883597A7 (fi) 1989-02-05
PT88187A (pt) 1989-06-30
EG18751A (en) 1993-12-30
DK434188D0 (da) 1988-08-03
FI883597A0 (fi) 1988-08-01
NO883414L (no) 1989-02-06
DE3856112T2 (de) 1998-08-27
PT88187B (pt) 1995-12-29
EP0540859B1 (en) 1998-01-14
CA1336887C (en) 1995-09-05
EP0302473A3 (en) 1990-01-17
EP0302473B1 (en) 1995-02-15
HUT47437A (en) 1989-03-28
JP2738414B2 (ja) 1998-04-08
IE68309B1 (en) 1996-06-12
JPH10130295A (ja) 1998-05-19
PT101702B (pt) 1999-11-30
ATE118354T1 (de) 1995-03-15
DE3853028D1 (de) 1995-03-23
HU207230B (en) 1993-03-29
NZ225599A (en) 1991-09-25
NO883414D0 (no) 1988-08-02
FI98197B (fi) 1997-01-31

Similar Documents

Publication Publication Date Title
ES2068191T3 (es) Conjugados anticuerpo-enzima en combinacion con profarmacos para el suministro de agentes citotoxicos a celulas tumorales.
AR032293A1 (es) Estuche farmaceutico
DE69013740D1 (de) Immunokonjugate und Prodrogen und ihre gemeinschaftliche Anwendung für die Verabreichung von Arzneimitteln.
DK0532525T3 (da) Nye protein-polykationkonjugater
ES2000743A6 (es) Estuche y procedimiento para preparar una unidad de dosificacion de activador de plasminogeno de tejidos humanos.
ES2018729A6 (es) Un metodo para preparar una variante de activador de plasmogeno de tejido.
BR0014826A (pt) Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm
GT199800152A (es) Formulacion medicamentosa con liberacion controlada de sustancia activa.
ES2080037T3 (es) Medicamento de uso topico con actividad cicatrizante.
ES2043696T3 (es) Derivados de prostaglandina e1 (derivados-pge1) como substancias activas farmaceuticas y medicamentos que contienen estos compuestos, especialmente para aplicacion transcutanea.
ES2103486T3 (es) Medicamentos que contienen acidos difosfonicos y sus sales.
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
US6342520B1 (en) Locally injectable chemotherapeutics
KR940006600A (ko) 혈전용해의 활성을 가지는 의약품의 제조를 위한 트롬빈의 직접적인 억제제의 이용
PE43995A1 (es) Procedimiento para la prevencion de la degradacion de la proteina c
Milhaud et al. Requirement for endocytosis of poly (rI). poly (rC) to generate toxicity on interferon-treated LM cells
MXPA02009376A (es) Compuestos para direccion al objetivo.
ES2142407T3 (es) Antimalaria.
OA09519A (fr) D-acide aspartique b-hydroxamate en tant que medicament
GR3002665T3 (en) Use of nitrophenyl groups for stimulating the capability of incorporation of a drug into the sensitive cells of a host
ATE67674T1 (de) Pharmazeutische zubereitungen mit heilender aktivitaet.
ECSP982522A (es) Modificacion a cristal de una sustancia activa de medicamento (ii)
ES2113904T3 (es) Profarmacos de antraciclinas.
MX9706461A (es) Sales de acido clavulanico.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 302473

Country of ref document: ES